Skip to main content

Advertisement

SpringerLink
Log in

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

CT-P13 is the first biosimilar monoclonal antibody to infliximab. However, the antibody was tested only in rheumatoid arthritis and ankylosing spondylitis, which demonstrated equivalence to the originator in efficacy, safety, and pharmacokinetic profile. Extrapolation of its efficacy and safety to other pathologies is tenuous. Interchangeability with its originator is another unclear area.

Aim

We aimed to describe the experience of CT-P13 use in inflammatory bowel disease at a tertiary center.

Methods

Seventeen subjects diagnosed with Crohn’s disease (CD, n = 8) or ulcerative colitis (UC, n = 9) who were administered CT-P13 from November 2012 to October 2013 at Dongguk University Ilsan Hospital were retrospectively enrolled. Medical records analyzed included patients’ characteristics, previous history of anti-tumor necrosis factor administration, response and remission to this biosimilar antibody, disease flare-up, and adverse drug reaction.

Results

Male–female ratio was 1.8. Mean age was 35.4 years (range 15–57). Mean number of CT-P13 administrations was 4.2 ± 1.9. Induction treatments were done in five UC and three CD patients. Clinical response and remission at 8 weeks were achieved in seven patients (five UC and two CD). One CD patient did not respond to CT-P13. Nine patients in maintenance with the originator were interchanged with CT-P13 (four UC and five CD patients). One UC patient experienced arthralgia and CT-P13 was discontinued. One patient experienced loss of response during the study period.

Conclusions

CT-P13 may have biosimilarity and interchangeability with its originator in inflammatory bowel disease. A large, randomized, double-blind, prospective study is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease—seven years on. Aliment Pharmacol Ther. 2006;23:451–463.

    Article  CAS  PubMed  Google Scholar 

  2. Norum J, Koldingsnes W, Aanes T, et al. The economic burden of TNFα inhibitors and other biologic treatments in Norway. ClinicoEconomics Outcomes Res (CEOR). 2011;3:73.

    Article  Google Scholar 

  3. World Health Organization. WHO expert committee on biological standardization. World Health Organ Tech Rep Ser. 2013;978:1–384, back cover.

  4. Kanase SJ, Gavhane YN, Khandekar A, et al. Biosimilar: an overview. Int J Pharm Sci Res. 2013;4:2132–2144.

    CAS  Google Scholar 

  5. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1:457–462.

    Article  CAS  PubMed  Google Scholar 

  6. Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol. 2009;6:550–552.

    Article  PubMed  Google Scholar 

  7. Generic Pharmaceutical Association. Savings achieved through the use of generic pharmaceuticals 2000–2009. http://www.gphaonline.org/sites/default/files/GPhA%20Savings%20Study%20Book%20Updated%20Web%20FINAL%20Jul23%2010_0.pdf. Accessed 12 May 2011.

  8. Epstein MS, Ehrenpreis ED, Kulkarni PM. Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol. 2014. doi:10.1038/ajg.2014.151.

  9. Weise M, Bielsky M-C, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–5117.

    Article  CAS  PubMed  Google Scholar 

  10. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Dignass A, Van Assche G, Lindsay J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohn’s Colitis. 2010;4:28–62.

    Article  CAS  Google Scholar 

  13. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations. Washington, DC: Food and Drug Administration; 2003.

    Google Scholar 

  14. Best WR, Becktel J, Singleton J, et al. Development of a Crohn’s disease activity index. Gastroenterology. 1976;70:439–444.

    CAS  PubMed  Google Scholar 

  15. D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–786.

    Article  PubMed  Google Scholar 

  16. Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117:761–769.

    Article  CAS  PubMed  Google Scholar 

  17. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.

    Article  CAS  PubMed  Google Scholar 

  18. Travis S, Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterol. 2006;30:17.

    Google Scholar 

  19. Clark M, Colombel J-F, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology. 2007;133:312–339.

    Article  PubMed  Google Scholar 

  20. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997;337:1029–1036.

    Article  CAS  PubMed  Google Scholar 

  21. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.

    Article  CAS  PubMed  Google Scholar 

  22. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17:S176–S185.

    Article  PubMed  Google Scholar 

  23. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849–853.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Rutgeerts P, Feagan B, Olson A, et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: act 1 trial. Gastroenterology. 2005;128:A105.

    Article  Google Scholar 

  25. Sandborn W, Reinisch W, Rachmilewitz D, et al. Infliximab induction and maintenance therapy for ulcerative colitis: the act 2 trial. Zeitschrift für Gastroenterologie. 2005;43:V6.

    Article  Google Scholar 

  26. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol. 2000;95:3490–3497.

    Article  CAS  PubMed  Google Scholar 

  27. Colombel J-F, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, College of Medicine, Dongguk University Ilsan Hospital, Goyang, 410-773, Republic of Korea

    Yun-Seong Kang, Hyoung Ho Moon, Seung Eun Lee, Yun Jeong Lim & Hyoun Woo Kang

Authors
  1. Yun-Seong Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyoung Ho Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seung Eun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yun Jeong Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hyoun Woo Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hyoun Woo Kang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kang, YS., Moon, H.H., Lee, S.E. et al. Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci 60, 951–956 (2015). https://doi.org/10.1007/s10620-014-3392-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-014-3392-z

Keywords

Search

Navigation